DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://www.nature.com/articles/onc2011195, but it redirected us to https://www.nature.com/articles/onc2011195. The analysis below is for the second page.

Title[redir]:
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma | Oncogene
Description:
Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in disease relapse and high mortality. High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling pathways has been implicated in the development of chemoresistance in cancer. Previously, our studies showed that high expression of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely with disease- and failure-free survival. In this study, we have implicated activated hedgehog (Hh) signaling pathway as a key factor behind high ABCG2 expression in DLBCL through direct upregulation of ABCG2 gene transcription. We have identified a single binding site for GLI transcription factors in the ABCG2 promoter and established its functionality using luciferase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays. Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions. This suggests a role for the stromal microenvironment in maintaining high levels of ABCG2 and GLI1. Accordingly, in vitro co-culture of DLBCL cells with HS-5 stromal cells increased ABCG2 mRNA and protein levels by paracrine activation of Hh signaling. In addition to ABCG2, co-culture of DLBCL cells with HS-5 cells also resulted in increase expression of the antiapoptotic proteins BCL2, BCL-xL and BCL2A1 and in induced chemotolerance to doxorubicin and methotrexate, drugs routinely used for the treatment of DLBCL. Similarly, activation of Hh signaling in DLBCL cell lines with recombinant Shh N-terminal peptide resulted in increased expression of BCL2 and ABCG2 associated with increased chemotolerance. Finally, functional inhibition of ABCG2 drug efflux activity with fumitremorgin C or inhibition of Hh signaling with cyclopamine-KAAD abrogated the stroma-induced chemotolerance suggesting that targeting ABCG2 and Hh signaling may have therapeutic value in overcoming chemoresistance in DLBCL.

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We find it hard to spot revenue streams.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

article, google, scholar, cas, cancer, abcg, lymphoma, cells, resistance, cell, expression, hedgehog, bcell, res, nature, signaling, large, diffuse, gene, leukemia, drug, dlbcl, gli, access, oncogene, protein, multidrug, pathway, breast, content, information, singh, transporter, cookies, high, tumor, stromal, regulation, pubmed, rev, patients, acute, biol, anderson, center, research, privacy, data, target, survival,

Topics {✒️}

nature portfolio permissions reprints pi3k/akt/gsk3/cdk pathway privacy policy atp-binding cassette g2 author information authors nature 411 nature cancer research advertising mxr/bcrp/abcp-overexpressing cells versatile tools protein bcrp/mxr/abcp/abcg2 social media research b-cell malignancies oci-ly10 cell lines wnt signalling pathways beta-trcp ubiquitin ligase real-time quantitative pcr nci/nih grant ca16672 ruela-de-sousa rr stroma-induced drug tolerance nucleotide sequence data myeloma cell resistance fludarabine-based induction therapy stroma-induced chemotolerance suggesting shh-ptc1 pathway doxorubicin-resistant thyroid cancer tumor cell survival springerlink instant access hedgehog signaling pathway atp-dependent transporters stromal cell microenvironment single binding site lymphoma tissue banks protects germinal center permissions bcrp/mxr/abcp cell-activating factor abcg2/mxr/abcp gli transcription factors dlbcl cell lines bcrp gene polymorphisms personal data regulating cell cycle multiple myeloma cells cancer drug resistance hedgehog-induced survival abcg2 gene transcription

Schema {🗺️}

WebPage:
      mainEntity:
         headline:ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma
         description:Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in disease relapse and high mortality. High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling pathways has been implicated in the development of chemoresistance in cancer. Previously, our studies showed that high expression of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely with disease- and failure-free survival. In this study, we have implicated activated hedgehog (Hh) signaling pathway as a key factor behind high ABCG2 expression in DLBCL through direct upregulation of ABCG2 gene transcription. We have identified a single binding site for GLI transcription factors in the ABCG2 promoter and established its functionality using luciferase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays. Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions. This suggests a role for the stromal microenvironment in maintaining high levels of ABCG2 and GLI1. Accordingly, in vitro co-culture of DLBCL cells with HS-5 stromal cells increased ABCG2 mRNA and protein levels by paracrine activation of Hh signaling. In addition to ABCG2, co-culture of DLBCL cells with HS-5 cells also resulted in increase expression of the antiapoptotic proteins BCL2, BCL-xL and BCL2A1 and in induced chemotolerance to doxorubicin and methotrexate, drugs routinely used for the treatment of DLBCL. Similarly, activation of Hh signaling in DLBCL cell lines with recombinant Shh N-terminal peptide resulted in increased expression of BCL2 and ABCG2 associated with increased chemotolerance. Finally, functional inhibition of ABCG2 drug efflux activity with fumitremorgin C or inhibition of Hh signaling with cyclopamine-KAAD abrogated the stroma-induced chemotolerance suggesting that targeting ABCG2 and Hh signaling may have therapeutic value in overcoming chemoresistance in DLBCL.
         datePublished:2011-05-30T00:00:00Z
         dateModified:2011-05-30T00:00:00Z
         pageStart:4874
         pageEnd:4886
         sameAs:https://doi.org/10.1038/onc.2011.195
         keywords:
            B-cell lymphoma
            Cancer therapeutic resistance
            Cell signalling
            Gene regulation
            ABCG2
            ATP-binding cassettes
            hedgehog pathway
            GLI
            diffuse large B-cell lymphoma
            Medicine/Public Health
            general
            Internal Medicine
            Cell Biology
            Human Genetics
            Oncology
            Apoptosis
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig6_HTML.jpg
         isPartOf:
            name:Oncogene
            issn:
               1476-5594
               0950-9232
            volumeNumber:30
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:R R Singh
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:K Kunkalla
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C Qu
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E Schlette
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S S Neelapu
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F Samaniego
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F Vega
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma
      description:Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in disease relapse and high mortality. High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling pathways has been implicated in the development of chemoresistance in cancer. Previously, our studies showed that high expression of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely with disease- and failure-free survival. In this study, we have implicated activated hedgehog (Hh) signaling pathway as a key factor behind high ABCG2 expression in DLBCL through direct upregulation of ABCG2 gene transcription. We have identified a single binding site for GLI transcription factors in the ABCG2 promoter and established its functionality using luciferase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays. Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions. This suggests a role for the stromal microenvironment in maintaining high levels of ABCG2 and GLI1. Accordingly, in vitro co-culture of DLBCL cells with HS-5 stromal cells increased ABCG2 mRNA and protein levels by paracrine activation of Hh signaling. In addition to ABCG2, co-culture of DLBCL cells with HS-5 cells also resulted in increase expression of the antiapoptotic proteins BCL2, BCL-xL and BCL2A1 and in induced chemotolerance to doxorubicin and methotrexate, drugs routinely used for the treatment of DLBCL. Similarly, activation of Hh signaling in DLBCL cell lines with recombinant Shh N-terminal peptide resulted in increased expression of BCL2 and ABCG2 associated with increased chemotolerance. Finally, functional inhibition of ABCG2 drug efflux activity with fumitremorgin C or inhibition of Hh signaling with cyclopamine-KAAD abrogated the stroma-induced chemotolerance suggesting that targeting ABCG2 and Hh signaling may have therapeutic value in overcoming chemoresistance in DLBCL.
      datePublished:2011-05-30T00:00:00Z
      dateModified:2011-05-30T00:00:00Z
      pageStart:4874
      pageEnd:4886
      sameAs:https://doi.org/10.1038/onc.2011.195
      keywords:
         B-cell lymphoma
         Cancer therapeutic resistance
         Cell signalling
         Gene regulation
         ABCG2
         ATP-binding cassettes
         hedgehog pathway
         GLI
         diffuse large B-cell lymphoma
         Medicine/Public Health
         general
         Internal Medicine
         Cell Biology
         Human Genetics
         Oncology
         Apoptosis
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2011.195/MediaObjects/41388_2011_Article_BFonc2011195_Fig6_HTML.jpg
      isPartOf:
         name:Oncogene
         issn:
            1476-5594
            0950-9232
         volumeNumber:30
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:R R Singh
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:K Kunkalla
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C Qu
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E Schlette
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S S Neelapu
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F Samaniego
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F Vega
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Oncogene
      issn:
         1476-5594
         0950-9232
      volumeNumber:30
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:R R Singh
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:K Kunkalla
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:C Qu
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:E Schlette
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:S S Neelapu
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:F Samaniego
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:F Vega
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(1)

https://twitter.com/oncogenejournal

External Links {🔗}(266)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Prism.js
Zoom.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.79s.